Are elevated homocysteine levels at 24-28 weeks of gestation risk factors for preeclampsia and intrauterine growth restriction

CONCLUSION: Elevated plasma homocysteine level at 24-28 weeks of gestation is not a useful marker for the subsequent development of preeclampsia and intrauterine growht restriction.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:OBJECTIVE: The aim of this study whether elevated plasma homocysteine levels at 24-28 weeks of gestation is associated with subsequent development of preeclampsia or intrauterine growth restriction in pregnant women.

📊

Key Findings & Data:STUDY DESIGN: This prospective study was conducted between April 2002 and June 2003, and involved 352 healthy pregnant women with who were at 24-28 weeks gestation.

💡

Conclusion & Impact:CONCLUSION: Elevated plasma homocysteine level at 24-28 weeks of gestation is not a useful marker for the subsequent development of preeclampsia and intrauterine growht restriction.

🔬Design:Research Article

📍Scope:2002 Verileri

⚙️Variables:Fetal gelişim geriliği · Homosistein · Preeklampsi

Abstract

OBJECTIVE: The aim of this study whether elevated plasma homocysteine levels at 24-28 weeks of gestation is associated with subsequent development of preeclampsia or intrauterine growth restriction in pregnant women. STUDY DESIGN: This prospective study was conducted between April 2002 and June 2003, and involved 352 healthy pregnant women with who were at 24-28 weeks gestation. Each woman's plasma homocysteine concentration was measured between 24-28 weeks. The homocysteine concentration for the entire cohort was used to generate 50th percentile values and the patients were categorized in two groups according to the quartile ranking of their homocysteine level. (Homocysteine above and below the 50th percentile) The two study groups were compared for vitamin B12 and folic acide levels, birthweight, gestational week and the incidence of preeclampsia, intrauterine growth restriction. RESULTS: There were no significant differences in the incidence of preeclampsia and IUGR between the two groups. For the infants, there were no significant differences for the gestational week and birthweight. Vitamin B12 and folic acide level was significantly lower in the high-homocysteine group than in the low-homocysteine group (p<0.05). CONCLUSION: Elevated plasma homocysteine level at 24-28 weeks of gestation is not a useful marker for the subsequent development of preeclampsia and intrauterine growht restriction.

Keywords

Fetal gelişim geriliği Homosistein Preeklampsi Gebelik Risk faktörleri Fetal Growth Retardation Homocysteine Pre-Eclampsia Pregnancy Risk Factors

🔖

Cite This Article

TARIM, E., KILIÇDAĞ, E., BAĞIŞ, T., ASLAN, E., ERKANLI, S., ŞİMŞEK, E., KUŞÇU, E. (2005). Are elevated homocysteine levels at 24-28 weeks of gestation risk factors for preeclampsia and intrauterine growth restriction. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 11 - Sayı: 1, 4–6. https://ajindex.com/articles/227141

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Hogg B, Tamura T, Johnston K, DuBard M, Goldenberg R. Second trimester homocysteine levels and pregnancy induced hypertension, preeclampsia, and intrauterine growth restriction. Am J Obstet 2000; 183:805-9
Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1:228-37
Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338:1042-50
Rajkovic A, Catalano PM, Malinow MR. Elevated homocysteine levels with preeclampsia. Obstet Gynecol 1997; 90:168-71
Raijmakers MT, Zusterzeel PL, Steegers EA, Peters WH. Hyperhomocysteinemia: a risk factor for preeclampsia? Eur J Obstet Gynecol Reprod Biol 2001; 95:226-8
Roberts JM, Redman CW. Preeclampsia: More than pregnancy-induced hypertension. Lancet 1993; 341:1447-51
Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354:407-13
Walker M, Smith G, Perkins S, Keely E, Garner P. Changes in homocystein levels during normal pregnancy. Am J Obstet Gynecol 1999; 180:660-4
De la Calle M, Usandizaga R, Sancha M, Magdaleno F, Herranz A, Cabrillo E. Homocystein, folic acid and B- group vitamins in obstetrics and gynaecology. Eur J Obstet Gynecol 2003; 107:125-34. 1O. Wouters MG, Thomas CM, Boers GH Hyperho¬mocysteinemia and pregnancy-review of our present understanding and therapeutic implications. Aubard Y, Darodes N, Cantaloube M. Eur J Obstet Gynecol 2000; 93:157-65
Plasma homocystein concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Powers R, Evans R, Majors A, Ojimba J, Ness R. Am J Obstet Gynecol 1998; 179:1605-11
Bostom AG, Lathrop L. Homocysteinemia in end-stage renal disease: Prevalance, etiology, and potential relationship to arteriosclerotis outcome. Kidney Int 1997; 52:10-20
Malinow MR, Rajkovic A, Duell PG, Hess DL, Upson BM. The relationship between maternal and neonatal umblical cord plasma homocysteine suggests a potential role for maternal homocysteine in fetal metabolism. Am J Obstet Gynecol 1998; 178:228-33.